Page 132 - 《中国药房》2025年11期

domized controlled trials[J]. Front Oncol，2023，13： 1362537.
1151769. [24] KANG R T，MA J L，AI B，et al. Efficacy and safety of
[14] DU J C，WANG X Y，FAN L W，et al. Effectiveness and immunotherapy combined with chemotherapy in patients
safety of first-line immune checkpoint inhibitors for pa‐ with ES-SCLC：a systematic review and network meta-
tients with extensive-stage small cell lung carcinoma：a analysis of RCTs and RWSs[J]. Thorac Cancer，2024，15
systematic review and network meta-analysis[J]. Heliyon， （33）：2375-2385.
2023，9（4）：e14794. [25] LIU Y，ZHU J，DU T Y，et al. Navigating first-line thera‐
[15] LI H J，HAN H D，LI C L，et al. Efficacy and safety of pies for extensive-stage small-cell lung cancer：a frequen‐
first-line PD-1/PD-L1 inhibitor combinations for tist network meta-analysis and systematic review[J]. Fu‐
extensive-stage small-cell lung cancer：a Bayesian net‐ ture Oncol，2024，20（28）：2109-2122.
work meta-analysis[J]. Ther Adv Med Oncol，2023，15： [26] 齐冉，聂旭阳，刘旭婷，等. 斯鲁利单抗联合化疗方案一
17588359231189430. 线治疗广泛期小细胞肺癌的药物经济学评价[J]. 中国药
[16] LONGO V，RIZZO A，CATINO A，et al. Safety evalua‐ 房，2023，34（11）：1368-1373.
tion of immune checkpoint inhibitors combined with che‐ [27] KANG S，LIU H L. Cost-effectiveness of adding serplu‐
motherapy for the treatment of small cell lung cancer：a limab to first-line chemotherapy for extensive-stage small-
meta-analysis of randomized controlled trials[J]. Thorac cell lung cancer in China[J]. Expert Rev Pharmacoecon
Cancer，2023，14（11）：1029-1035. Outcomes Res，2024，24（9）：1081-1088.
[17] SATHIYAPALAN A，FEBBRARO M，POND G R，et al. [28] LIANG X Y，CHEN X Y，LI H J，et al. Cost-effectiveness
Chemo-immunotherapy in first line extensive stage small analysis of first-line serplulimab combined with chemo‐
cell lung cancer（ES-SCLC）：a systematic review and therapy for extensive-stage small cell lung cancer[J].
meta-analysis[J]. Curr Oncol，2022，29（12）：9046-9065. Front Public Health，2023，11：1156427.
[18] WANG S X，LI Y S，LIU Z Q，et al. Efficacy and safety of [29] LONG Y C，XU Y，LIAO L，et al. Cost-effectiveness
first-line immune checkpoint inhibitors combined with analysis of serplulimab combined with chemotherapy in
chemotherapy for extensive-stage small cell lung cancer：a the treatment of extensive-stage small-cell lung cancer
network meta-analysis[J]. Lung Cancer，2023，178：47-56. from the perspective of the healthcare system in China[J].
[19] ZHANG T M，LI W J，DIWU D B，et al. Efficacy and BMJ Open，2023，13（8）：e072106.
safety of first-line immunotherapy plus chemotherapy in [30] SHAO T H，ZHAO M Y，LIANG L Y，et al. Serplulimab
treating patients with extensive-stage small cell lung can‐ plus chemotherapy vs. chemotherapy for treatment of US
cer：a Bayesian network meta-analysis[J]. Front Immunol， and Chinese patients with extensive-stage small-cell lung
2023，14：1197044. cancer：a cost-effectiveness analysis to inform drug pricing
[20] ZHAO W H，WANG S F，SU C Y，et al. Efficacy of first- [J]. BioDrugs，2023，37（3）：421-432.
line immunotherapy combined with chemotherapy in [31] XIANG G Y，JIANG T T，GAN L L，et al. Cost-
extensive-stage small cell lung cancer patients with diffe- effectiveness of serplulimab as first-line therapy for
rent brain metastases status：a systematic review and meta- extensive-stage small cell lung cancer in China[J]. Front
analysis[J]. World J Oncol，2023，14（6）：529-539. Immunol，2023，14：1223020.
[21] ZHU Y，LIU K，ZHU H，et al. Comparative efficacy and [32] ZHENG Z W，CHEN H C，CAI H F. Cost-effectiveness
safety of novel immuno-chemotherapy for extensive-stage analysis of serplulimab combination therapy versus che‐
small-cell lung cancer：a network meta-analysis of ran‐ motherapy alone for patients with extensive-stage small
domized controlled trial[J]. Ther Adv Med Oncol，2023， cell lung cancer[J]. Front Oncol，2024，13：1259574.
15：17588359231206147. [33] ZHU Y W，LIU K，QIN Q，et al. Serplulimab plus chemo‐
[22] YANG C，XUAN T T，GONG Q，et al. Efficacy and therapy as first-line treatment for extensive-stage small-
safety of novel immune checkpoint inhibitor-based combi‐ cell lung cancer：a cost-effectiveness analysis[J]. Front Im‐
nations versus chemotherapy as first-line treatment for pa‐ munol，2023，13：1044678.
tients with extensive-stage small cell lung cancer：a net‐ [34] YI L D，ZHOU Z，ZENG X H，et al. First-line treatments
work meta-analysis[J]. Thorac Cancer，2024，15（15）： for extensive-stage small-cell lung cancer with immune
1246-1262. checkpoint inhibitors plus chemotherapy：a China-based
[23] GONG S Y，LI Q，YU X，et al. Efficacy and safety of dif‐ cost-effectiveness analysis[J]. Front Immunol，2024，15：
ferent immunotherapies combined with chemotherapy as 1408928.
first-line therapy in patients with small cell lung cancer：a （收稿日期：2024-10-18 修回日期：2025-05-08）
network meta-analysis[J]. Front Immunol，2024，15： （编辑：孙 冰）

· 1410 · China Pharmacy 2025 Vol. 36 No. 11 中国药房 2025年第36卷第11期